- What's the reason for the rapid increase for Dantrolene?
- by Lee, in-bok Apr 29, 2020 06:20am
- Dantrolene, a muscle relaxant that was supplied in a very small quantity to be designated as an orphan drug, has recently attracted attention in the background as demand has increased in Korea. In the past, it was required to hold only in emergency medical centers in each region, but demand was low. However, there are increasing cases of usin
- Opinion
- [Reporter’s View] What COVID-19 revealed in drug industry
- by Kim, Jin-Gu Apr 29, 2020 06:20am
- The humanity will ultimately overcome the COVID-19 pandemic. But the problem is what follows next. Scholars around the world talk about the Post-COVID-19. Each of them theorizes their own seemingly realistic ideas of “New Normal.” Among all of their hypotheses, ‘giving science back to the public’ speaks to the heart. At an online
- Policy
- Issues to remain as restricting bioequivalence test scrapped
- by Lee, Tak-Sun Apr 29, 2020 06:19am
- The issues regarding highly saturated first generic market would likely to remain as the Regulatory Reform Committee has axed the Korea Ministry of Food and Drug Safety’s (MFDS) plan to restrict joint and cosigned bioequivalence test. Even if the government grants favorable pricing on generics with individual test data from July, the ind
- Policy
- The MOHW, support for pharmaceuticals entering overseas
- by Lee, Jeong-Hwan Apr 29, 2020 06:19am
- The government will create a &8361;100 billion fund to support domestic biohealth companies that have excellent technology but are having difficulty attracting external investment. The final goal of the fund is to enhance the international competitiveness of Korean bio-health companies and to expand into the global market due to the COVI
- Policy
- Amendment to cascading drug price revision proceeds as it is
- by Kim, Jung-Ju Apr 29, 2020 06:19am
- If the co-biological equivalence test 1 + 3 system is discarded by the Regulatory Reform Committee among the 'Regulation on Pharmaceuticals Approval, Notification and Review', what will happen to the 'cascading drug price revision' of ‘a partial revision of the Criteria for Decision or Adjustment on Drugs’? The MOHW plans to carry out t
- Opinion
- [Reporter’s view] Pharmacist's role to meet post COVID-19
- by Kim, Min-Gun Apr 29, 2020 04:59am
- COVID-19 is changing our lives and culture itself with more powerful infectious power than any other epidemic. Telecommuting and video conferencing, represented by social distance, began in earnest, and online shopping malls are booming. It is a daily routine of non-facing contact. Hong Nam-ki, Deputy Prime Minister and Minister of Economy
- Policy
- CSL, Australian company, licensed for business in Korea
- by Lee, Tak-Sun Apr 28, 2020 06:24am
- CSL, an Australian global pharmaceutical company, conducts full-scale marketing in Korea. It was the first time in the domestic pharmaceutical industry to acquire a business license and an item license. CSL Behring Korea, a subsidiary of CSL, received a drug import license from the MFDS on the 16th. General manager, Ji-Young Sohn, who ha
- Company
- General hospitals ready to prescribe Verzenio
- by Eo, Yun-Ho Apr 28, 2020 06:24am
- The general hospitals in Korea have started entering the anticancer treatment Verzenio’s prescription code. According to pharmaceutical industry sources, drug committees at major general hospitals like Seoul National University Hospital, National Cancer Center, Ajou University Hospital and Chonnam National University Hwasun Hospital have
- Company
- Boryung records new quarterly operating profit
- by Chon, Seung-Hyun Apr 28, 2020 06:23am
- Boryung showed good results in the first quarter. Despite COVID-19, operating profit was the largest ever. Sales also rose from last year. The self-developed drug 'Kanarb Family' led the improvement. Boryung announced on the 24th that its operating profit in the first quarter increased by 42.1% year-on-year to &8361;13.4 billion. During t
- Company
- Flu drug prescription plummets by 21% due to COVID-19
- by Kim, Jin-Gu Apr 28, 2020 06:23am
- The general prescription volume of influenza medications treatment has gone down drastically. Compared to the previous season, this season’s volume has plummeted by 21.0 percent. The flu treatment prescription seems to have been affected by the COVID-19 outbreak. The threat of the virus has particularly raised the awareness of personal hygi
